On March 10, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The accepted abstracts highlight research related to BriaCell’s cellular immunotherapy platform, including the Company’s ongoing pivotal Phase 3 study of Bria-IMTᵀᴹ in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612) and research supporting Bria-OTS+ᵀᴹ, BriaCell’s next-generation personalized off-the-shelf immunotherapy program.
Poster titles and presentation details will become available on March 17, 2026 at 4:30 PM ET, when the abstracts will be published in the online Proceedings of AACR (Free AACR Whitepaper).
(Press release, BriaCell Therapeutics, MAR 10, 2026, View Source [SID1234663436])